MONMOUTH JUNCTION, N.J. -
June 27, 2018 -
PRLog -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their lipid binding sample preparation technology for studying the tolerance of oocytes to chilling injuries when cytoplasmic lipid content is reduced. The citation is:
Barrera N, dos Santos Neto PC, Cuadro F, Bosolasco D, Mulet AP, Crispo M, et al. (2018) Impact of delipidated estrous sheep serum supplementation on
in vitro maturation, cryotolerance and endoplasmic reticulum stress gene expression of sheep oocytes. PLoS ONE 13(6): e0198742. http://journals.plos.org/
plosone/doi?
id=10.1371/journal.pone.0198742
High lipid content of oocytes and embryos in domestic animals is one of the well-known factors associated with poor cryosurvival. In this articles, the authors wanted to determine whether the use of delipidated estrous sheep serum during
in vitro maturation (IVM) of ovine oocytes reduces the cytoplasmic lipid droplets content and improves embryo development and cryotolerance after vitrification. The article states "Lipid removal from serum was performed by using Cleanascite™
(Biotech Support Group, NJ, USA) according to the instructions provided by the manufacturer. Unlike other approaches, the protocol described herein for delipidation of estrous sheep serum was effective in decreasing levels of Triglycerides, total Cholesterol, and NEFAs. To our knowledge this is the first study to use the Cleanascite method to generate estrous sheep serum yielding significantly reduced lipid levels. Subsequent use of the partially delipidated serum as supplemented in IVM media resulted in effective reduction of oocyte lipid content. The advantage of this method over other traditional methods (i.e. chloroform) includes increased feasibility and reduced toxicity and biosafety concerns" Their results demonstrate that although supplementation of IVM medium with delipidated estrous sheep serum reduces the presence of cytoplasmic lipid droplets in oocytes after maturation, oocyte cryotolerance is not improved.
"I am pleased to see another example of the versatility of
Cleanascite™. This demonstrates the advantage of using an aqueous suspension product with no harmful solvents, to deplete lipid associated factors that may influence cell response investigations."
states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
For more information visit:
Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htmAbout Biotech Support Group LLCConverging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™
for lipid adsorption, HemogloBind™
and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com
Contact:Matthew Kuruc 732-274-2866
mkuruc@biotechsupportgroup.com
Account Phone Number